Rafarma Pharmaceuticals arranged a meeting with CERES F&D Inc.




Rafarma Pharmaceuticals negotiated with the Ministry of Kazakhstan


Rafarma Pharmaceuticals is preparing to participate in a conference dedicated to modern neuroscience


Rafarma Pharmaceuticals registered NOYA THERAPEUTICS LTD company in Israel


Letter to the Shareholders from President Raivo Unt


Rafarma Pharmaceuticals plans to build a production unit of pharmacopeial substances in Yeruham


Rafarma Pharmaceuticals has entered into negotiations with Israel Ariel University

Rafarma Pharmaceuticals appoints pharmaceutical industry leader Unt Raivo as new CEO

Slavich Noya Technology announces H1 2022 results


Rafarma Pharmaceuticals is continuing to develop smart packaging for a wide range of medicines

Rafarma Pharmaceuticals has signed an agreement with Istem Medikal


Rafarma Pharmaceuticals strengthens its position in Central Asia


Rafarma Pharmaceuticals develops new liposome-based medicine for targeted therapy

Rafarma Pharmaceuticals has developed a non-hardening gel for the radiopharmaceutical market


Rafarma Pharmaceuticals has entered into negotiations with the Institute of Isotopes Co. Ltd.


Rafarma Pharmaceuticals is working on a dietary supplement for the neurological deficits’ treatment

Rafarma Pharmaceuticals’ project was included in the state program of Uzbekistan
Rafarma’s Slavich Noya Technology Division Expands Printing Production
RAFA Enters into Negotiations with JINR for Ultra-Cutting Edge Nuclear Research